Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

In this free webinar, learn about the importance of customizing randomization and trial supply management (RTSM) site resupply algorithms to balance investigational medicinal product (IMP) supply ...

AstraZeneca and Daiichi Sankyo will hear back from the FDA before the end of 2022 on their license application for Enhertu in HER2-low breast cancer – an indication which could drive the drug ...

Trodelvy shows consistent efficacy in metastatic triple-negative breast cancer with a 27.8% ORR and 4.8 months PFS. Enhertu demonstrates promising results in HER2-low patients post-Trodelvy, achieving ...

55% of BriaCell patients 1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients Multiple ...

In DESTINY-Breast03, around 10% of patients treated with Enhertu developed ILD or pneumonitis, compared to less than 2% of the Kadcyla group, although most of the cases were grade 1 and 2 and none ...

For example, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) brought in revenues of more than $2.5 billion for these partners in 2023, which was its fourth full year on the market.

Huge, intensely competitive markets. The market leading antibody-drug conjugate, Enhertu (co-owned by Daiichi Sankyo and AstraZeneca), uses a derivative of exatecan (deruxtecan) as its warhead.

Lola McEvoy is set to press the government upon the use of Enhertu after the death of Heather Sawyer - a Darlington grandmother who campaigned for the drug she believed would have extended her life.

This webinar will delve into the intricate landscape of combination drug therapy, exploring the scientific, regulatory, and commercial challenges involved, while also highlighting the significant ...

The drug, called Enhertu, can give patients with a specific type of incurable breast cancer an extra six months to live on average. The health assessment body, NICE, is the only organisation ...